Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 known ✓ | O94806 | 2/20 | 0.98 |
| ▸ | PRKD1 known ✓ | Q15139 | 2/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.41 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.98 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | SRPK2 | P78362 | 1/20 | 0.39 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | WNT1 | P04628 | 7/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.37 |
| ▸ | GSK3B | P49841 | 6/20 | 0.37 |
| ▸ | CLK2 | P49760 | 1/20 | 0.37 |
| ▸ | CLK3 | P49761 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514722 | 0.99 | PRKD3 (1.00) | PRKD3PRKD1PRKD2KCNH2ATM | |
| SCHEMBL4514725 | 0.99 | PRKD3 (1.00) | PRKD3PRKD1PRKD2KCNH2ATM | |
| SCHEMBL4514713 | 0.99 | PRKD3 (1.00) | PRKD3PRKD1PRKD2KCNH2ATM | |
| SCHEMBL4512250 | 0.86 | PRKD3 (0.77) | PRKD3PRKD1PRKD2ATRWNT1 | |
| SCHEMBL4512245 | 0.86 | PRKD3 (0.77) | PRKD3PRKD1PRKD2ATRWNT1 | |
| SCHEMBL4512238 | 0.86 | PRKD3 (0.77) | PRKD3PRKD1PRKD2ATRWNT1 | |
| SCHEMBL4510835 | 0.86 | PRKD3 (0.77) | PRKD3PRKD1PRKD2KCNH2ATM | |
| SCHEMBL4510827 | 0.86 | PRKD3 (0.77) | PRKD3PRKD1PRKD2KCNH2ATM | |
| SCHEMBL4510838 | 0.86 | PRKD3 (0.77) | PRKD3PRKD1PRKD2KCNH2ATM | |
| SCHEMBL14865912 | 0.85 | PRKD3 (0.75) | PRKD3PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025051709-A1 | METHODS FOR THE DIAGNOSIS, TREATMENT AND CHARACTERIZATION OF NLRP3-ASSOCIATED AUTOINFLAMMATORY DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-03-13 | — | — | WO | claimed |
| WO-2022234494-A2 | METHODS AND COMPOSITIONS FOR INTERFERING WITH FAN1 | THE HOSPITAL FOR SICK CHILDREN (CA) | 2022-11-10 | — | — | WO | claimed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| WO-2025051709-A1 | METHODS FOR THE DIAGNOSIS, TREATMENT AND CHARACTERIZATION OF NLRP3-ASSOCIATED AUTOINFLAMMATORY DISEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-03-13 | — | — | WO | disclosed |
| US-20240390406-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTIAGING DRUGS | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2024-11-28 | — | — | US | disclosed |
| EP-4467978-A1 | PHOSPHORYLATED TRISTETRAPROLIN AS A BIOMARKER AND THERAPEUTIC TARGET FOR ANTI-AGING DRUGS | King Faisal Specialist Hospital & Research Centre (SA) | 2024-11-27 | — | — | EP | disclosed |
| EP-3735587-B1 | SYNCHRONIZED CELL CYCLE GENE EXPRESSION TEST FOR ALZHEIMER'S DISEASE AND RELATED THERAPEUTIC METHODS | NEUROGX LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4412621-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT Bio Corp. (US) | 2024-08-14 | — | — | EP | disclosed |
| US-20240252688-A1 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. | 2024-08-01 | — | — | US | disclosed |
| CN-118077454-A | Application of sprouting lactone in promoting rice growth under saline-alkali stress condition | 中国科学院东北地理与农业生态研究所 | 2024-05-28 | — | — | CN | disclosed |
| US-20240082260-A1 | INHIBITOR OF PROTEIN KINASE D FOR USE IN PREVENTION OR TREATMENT OF HYPERLIPIDEMIA | INST BIOLOGII DOSWIADCZALNEJ IMIENIA MARCELEGO NENCKIEGO POLSKIEJ AKADEMII NAUK (PL) | 2024-03-14 | — | — | US | disclosed |
| CN-111699386-B | Synchronized cell cycle gene expression assays for Alzheimer's disease and related therapeutic methods | 神经GX有限责任公司 | 2023-08-18 | — | — | CN | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| WO-2023056202-A2 | COMPOSITIONS AND METHODS FOR ENHANCED PROTEIN PRODUCTION | HDT BIO CORP. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-4138840-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC AND CARDIOVASCULAR DISEASES | University of Rochester (US) | 2023-03-01 | — | — | EP | disclosed |
| WO-2022234494-A2 | METHODS AND COMPOSITIONS FOR INTERFERING WITH FAN1 | THE HOSPITAL FOR SICK CHILDREN (CA) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022185253-A1 | INHIBITOR OF PROTEIN KINASE D FOR USE IN PREVENTION OR TREATMENT OF HYPERLIPIDEMIA | Instytut Biologii doswiadczalnej imienia Marcelego Nenckiego Polskiej Akademii Nauk (PL) | 2022-09-09 | — | — | WO | disclosed |
| EP-4052700-A1 | INHIBITOR OF PROTEIN KINASE D (PKD) FOR USE IN PREVENTION OR TREATMENT OF OBESITY AND A PHARMACEUTICAL COMPOSITION FOR SUCH USE | Instytut Biologii doswiadczalnej imienia Marcelego Nenckiego Polskiej Akademii Nauk (PL) | 2022-09-07 | — | — | EP | disclosed |
| CN-109722411-B | Application method of micromolecules for promoting self-renewal state of embryonic stem cells | 安徽大学 | 2022-05-06 | — | — | CN | disclosed |
| EP-3980560-A1 | SYNCHRONIZED CELL CYCLE GENE EXPRESSION TEST FOR ALZHEIMER'S DISEASE | NeuroGX LLC (US) | 2022-04-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082260-A1 | INHIBITOR OF PROTEIN KINASE D FOR USE IN PREVENTION OR TREATMENT OF HYPERLIPIDEMIA | PCSK9, PRKD3, PRKCA | PRKD3 2/4885PRKD1 7/4885KCNH2 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.